nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—CYP3A4—type 2 diabetes mellitus	0.0898	1	CbGaD
Regorafenib—UGT1A9—Nateglinide—type 2 diabetes mellitus	0.0493	0.0965	CbGbCtD
Regorafenib—UGT1A1—Losartan—type 2 diabetes mellitus	0.0249	0.0488	CbGbCtD
Regorafenib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0216	0.0422	CbGbCtD
Regorafenib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0173	0.0337	CbGbCtD
Regorafenib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0164	0.0321	CbGbCtD
Regorafenib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0156	0.0305	CbGbCtD
Regorafenib—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0154	0.0301	CbGbCtD
Regorafenib—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0151	0.0294	CbGbCtD
Regorafenib—ABCG2—Glyburide—type 2 diabetes mellitus	0.015	0.0293	CbGbCtD
Regorafenib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0146	0.0286	CbGbCtD
Regorafenib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0144	0.0282	CbGbCtD
Regorafenib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0139	0.0272	CbGbCtD
Regorafenib—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0138	0.0269	CbGbCtD
Regorafenib—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0131	0.0256	CbGbCtD
Regorafenib—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0131	0.0256	CbGbCtD
Regorafenib—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0128	0.025	CbGbCtD
Regorafenib—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.0121	0.0236	CbGbCtD
Regorafenib—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.0117	0.0228	CbGbCtD
Regorafenib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.0113	0.0222	CbGbCtD
Regorafenib—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.0109	0.0213	CbGbCtD
Regorafenib—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.0109	0.0213	CbGbCtD
Regorafenib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0106	0.0207	CbGbCtD
Regorafenib—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.01	0.0196	CbGbCtD
Regorafenib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00982	0.0192	CbGbCtD
Regorafenib—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0097	0.019	CbGbCtD
Regorafenib—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00887	0.0173	CbGbCtD
Regorafenib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00875	0.0171	CbGbCtD
Regorafenib—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00825	0.0161	CbGbCtD
Regorafenib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00801	0.0157	CbGbCtD
Regorafenib—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00791	0.0155	CbGbCtD
Regorafenib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00731	0.0143	CbGbCtD
Regorafenib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00726	0.0142	CbGbCtD
Regorafenib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.007	0.0137	CbGbCtD
Regorafenib—CYP2C19—Glyburide—type 2 diabetes mellitus	0.0067	0.0131	CbGbCtD
Regorafenib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00633	0.0124	CbGbCtD
Regorafenib—CYP2C19—Losartan—type 2 diabetes mellitus	0.00613	0.012	CbGbCtD
Regorafenib—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00557	0.0109	CbGbCtD
Regorafenib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00541	0.0106	CbGbCtD
Regorafenib—CYP2C9—Losartan—type 2 diabetes mellitus	0.0051	0.00996	CbGbCtD
Regorafenib—ABCB1—Losartan—type 2 diabetes mellitus	0.00495	0.00967	CbGbCtD
Regorafenib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0048	0.00938	CbGbCtD
Regorafenib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0046	0.00899	CbGbCtD
Regorafenib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0046	0.00899	CbGbCtD
Regorafenib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00435	0.0085	CbGbCtD
Regorafenib—PDGFRA—penis—type 2 diabetes mellitus	0.00345	0.0446	CbGeAlD
Regorafenib—RET—autonomic nervous system—type 2 diabetes mellitus	0.00341	0.0441	CbGeAlD
Regorafenib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00324	0.00634	CbGbCtD
Regorafenib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00296	0.00579	CbGbCtD
Regorafenib—KDR—hindlimb—type 2 diabetes mellitus	0.00235	0.0304	CbGeAlD
Regorafenib—FLT4—endothelium—type 2 diabetes mellitus	0.00185	0.0239	CbGeAlD
Regorafenib—TEK—artery—type 2 diabetes mellitus	0.00176	0.0228	CbGeAlD
Regorafenib—FLT1—artery—type 2 diabetes mellitus	0.0017	0.022	CbGeAlD
Regorafenib—TEK—endothelium—type 2 diabetes mellitus	0.00149	0.0192	CbGeAlD
Regorafenib—DDR2—retina—type 2 diabetes mellitus	0.00148	0.0191	CbGeAlD
Regorafenib—KDR—artery—type 2 diabetes mellitus	0.00144	0.0186	CbGeAlD
Regorafenib—FLT1—endothelium—type 2 diabetes mellitus	0.00144	0.0186	CbGeAlD
Regorafenib—DDR2—cardiovascular system—type 2 diabetes mellitus	0.00125	0.0161	CbGeAlD
Regorafenib—KDR—endothelium—type 2 diabetes mellitus	0.00122	0.0157	CbGeAlD
Regorafenib—DDR2—adipose tissue—type 2 diabetes mellitus	0.0011	0.0142	CbGeAlD
Regorafenib—KIT—endothelium—type 2 diabetes mellitus	0.00108	0.0139	CbGeAlD
Regorafenib—MAPK11—adipose tissue—type 2 diabetes mellitus	0.00104	0.0135	CbGeAlD
Regorafenib—EPHX2—retina—type 2 diabetes mellitus	0.000997	0.0129	CbGeAlD
Regorafenib—EPHX2—nephron tubule—type 2 diabetes mellitus	0.000939	0.0121	CbGeAlD
Regorafenib—Sorafenib—ABCC2—type 2 diabetes mellitus	0.00092	0.334	CrCbGaD
Regorafenib—EPHA2—islet of Langerhans—type 2 diabetes mellitus	0.000867	0.0112	CbGeAlD
Regorafenib—FRK—liver—type 2 diabetes mellitus	0.000861	0.0111	CbGeAlD
Regorafenib—FLT1—islet of Langerhans—type 2 diabetes mellitus	0.000818	0.0106	CbGeAlD
Regorafenib—Sorafenib—HTR2C—type 2 diabetes mellitus	0.000814	0.295	CrCbGaD
Regorafenib—RAF1—islet of Langerhans—type 2 diabetes mellitus	0.000813	0.0105	CbGeAlD
Regorafenib—EPHX2—cortex of kidney—type 2 diabetes mellitus	0.000804	0.0104	CbGeAlD
Regorafenib—BRAF—adipose tissue—type 2 diabetes mellitus	0.000778	0.0101	CbGeAlD
Regorafenib—DDR2—liver—type 2 diabetes mellitus	0.000772	0.00999	CbGeAlD
Regorafenib—FLT4—cardiovascular system—type 2 diabetes mellitus	0.000761	0.00984	CbGeAlD
Regorafenib—UGT1A9—kidney—type 2 diabetes mellitus	0.000755	0.00976	CbGeAlD
Regorafenib—EPHX2—adipose tissue—type 2 diabetes mellitus	0.000744	0.00962	CbGeAlD
Regorafenib—FLT4—cortex of kidney—type 2 diabetes mellitus	0.000725	0.00937	CbGeAlD
Regorafenib—FGFR1—cortex of kidney—type 2 diabetes mellitus	0.000715	0.00925	CbGeAlD
Regorafenib—FLT1—retina—type 2 diabetes mellitus	0.000699	0.00904	CbGeAlD
Regorafenib—EPHA2—nephron tubule—type 2 diabetes mellitus	0.000698	0.00903	CbGeAlD
Regorafenib—FLT4—adipose tissue—type 2 diabetes mellitus	0.000671	0.00867	CbGeAlD
Regorafenib—FGFR1—adipose tissue—type 2 diabetes mellitus	0.000662	0.00856	CbGeAlD
Regorafenib—FLT1—nephron tubule—type 2 diabetes mellitus	0.000658	0.00852	CbGeAlD
Regorafenib—RET—kidney—type 2 diabetes mellitus	0.000657	0.0085	CbGeAlD
Regorafenib—RAF1—nephron tubule—type 2 diabetes mellitus	0.000655	0.00847	CbGeAlD
Regorafenib—FGFR2—cardiovascular system—type 2 diabetes mellitus	0.000638	0.00825	CbGeAlD
Regorafenib—EPHA2—cardiovascular system—type 2 diabetes mellitus	0.000627	0.00811	CbGeAlD
Regorafenib—FGFR2—kidney—type 2 diabetes mellitus	0.000624	0.00807	CbGeAlD
Regorafenib—Sorafenib—CYP1A2—type 2 diabetes mellitus	0.000614	0.223	CrCbGaD
Regorafenib—TEK—cardiovascular system—type 2 diabetes mellitus	0.000612	0.00791	CbGeAlD
Regorafenib—EPHA2—pancreas—type 2 diabetes mellitus	0.000609	0.00788	CbGeAlD
Regorafenib—TEK—kidney—type 2 diabetes mellitus	0.000599	0.00774	CbGeAlD
Regorafenib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000598	0.00774	CbGeAlD
Regorafenib—TEK—pancreas—type 2 diabetes mellitus	0.000595	0.00769	CbGeAlD
Regorafenib—FLT1—cardiovascular system—type 2 diabetes mellitus	0.000591	0.00765	CbGeAlD
Regorafenib—KDR—retina—type 2 diabetes mellitus	0.000591	0.00764	CbGeAlD
Regorafenib—RAF1—cardiovascular system—type 2 diabetes mellitus	0.000588	0.0076	CbGeAlD
Regorafenib—TEK—cortex of kidney—type 2 diabetes mellitus	0.000583	0.00754	CbGeAlD
Regorafenib—FLT1—kidney—type 2 diabetes mellitus	0.000579	0.00748	CbGeAlD
Regorafenib—RAF1—kidney—type 2 diabetes mellitus	0.000575	0.00744	CbGeAlD
Regorafenib—FLT1—pancreas—type 2 diabetes mellitus	0.000575	0.00743	CbGeAlD
Regorafenib—RAF1—pancreas—type 2 diabetes mellitus	0.000572	0.00739	CbGeAlD
Regorafenib—FLT1—cortex of kidney—type 2 diabetes mellitus	0.000564	0.00729	CbGeAlD
Regorafenib—FGFR2—adipose tissue—type 2 diabetes mellitus	0.000563	0.00728	CbGeAlD
Regorafenib—RAF1—cortex of kidney—type 2 diabetes mellitus	0.00056	0.00725	CbGeAlD
Regorafenib—KDR—nephron tubule—type 2 diabetes mellitus	0.000557	0.0072	CbGeAlD
Regorafenib—PDGFRA—cardiovascular system—type 2 diabetes mellitus	0.000554	0.00717	CbGeAlD
Regorafenib—EPHA2—adipose tissue—type 2 diabetes mellitus	0.000553	0.00715	CbGeAlD
Regorafenib—BRAF—liver—type 2 diabetes mellitus	0.000546	0.00706	CbGeAlD
Regorafenib—TEK—adipose tissue—type 2 diabetes mellitus	0.000539	0.00698	CbGeAlD
Regorafenib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000533	0.0069	CbGeAlD
Regorafenib—EPHX2—liver—type 2 diabetes mellitus	0.000522	0.00675	CbGeAlD
Regorafenib—FLT1—adipose tissue—type 2 diabetes mellitus	0.000522	0.00674	CbGeAlD
Regorafenib—RAF1—adipose tissue—type 2 diabetes mellitus	0.000518	0.00671	CbGeAlD
Regorafenib—UGT1A1—kidney—type 2 diabetes mellitus	0.000517	0.00669	CbGeAlD
Regorafenib—KDR—cardiovascular system—type 2 diabetes mellitus	0.0005	0.00647	CbGeAlD
Regorafenib—KIT—nephron tubule—type 2 diabetes mellitus	0.000493	0.00638	CbGeAlD
Regorafenib—KDR—kidney—type 2 diabetes mellitus	0.000489	0.00633	CbGeAlD
Regorafenib—PDGFRA—adipose tissue—type 2 diabetes mellitus	0.000489	0.00632	CbGeAlD
Regorafenib—UGT1A9—liver—type 2 diabetes mellitus	0.000477	0.00617	CbGeAlD
Regorafenib—KDR—cortex of kidney—type 2 diabetes mellitus	0.000476	0.00616	CbGeAlD
Regorafenib—FLT4—liver—type 2 diabetes mellitus	0.00047	0.00608	CbGeAlD
Regorafenib—FGFR1—liver—type 2 diabetes mellitus	0.000464	0.006	CbGeAlD
Regorafenib—ABL1—retina—type 2 diabetes mellitus	0.000456	0.0059	CbGeAlD
Regorafenib—KIT—cardiovascular system—type 2 diabetes mellitus	0.000443	0.00573	CbGeAlD
Regorafenib—KDR—adipose tissue—type 2 diabetes mellitus	0.000441	0.0057	CbGeAlD
Regorafenib—KIT—kidney—type 2 diabetes mellitus	0.000433	0.00561	CbGeAlD
Regorafenib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.000433	0.0056	CbGeAlD
Regorafenib—KIT—pancreas—type 2 diabetes mellitus	0.000431	0.00557	CbGeAlD
Regorafenib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000429	0.00555	CbGeAlD
Regorafenib—PDGFRB—kidney—type 2 diabetes mellitus	0.000423	0.00548	CbGeAlD
Regorafenib—KIT—cortex of kidney—type 2 diabetes mellitus	0.000422	0.00546	CbGeAlD
Regorafenib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000421	0.00544	CbGeAlD
Regorafenib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.000412	0.00533	CbGeAlD
Regorafenib—Sorafenib—CYP3A4—type 2 diabetes mellitus	0.000407	0.148	CrCbGaD
Regorafenib—FGFR2—liver—type 2 diabetes mellitus	0.000395	0.0051	CbGeAlD
Regorafenib—KIT—adipose tissue—type 2 diabetes mellitus	0.000391	0.00505	CbGeAlD
Regorafenib—EPHA2—liver—type 2 diabetes mellitus	0.000388	0.00502	CbGeAlD
Regorafenib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000386	0.00499	CbGeAlD
Regorafenib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.000382	0.00494	CbGeAlD
Regorafenib—TEK—liver—type 2 diabetes mellitus	0.000378	0.00489	CbGeAlD
Regorafenib—ABL1—kidney—type 2 diabetes mellitus	0.000377	0.00488	CbGeAlD
Regorafenib—ABL1—pancreas—type 2 diabetes mellitus	0.000375	0.00485	CbGeAlD
Regorafenib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000368	0.00475	CbGeAlD
Regorafenib—FLT1—liver—type 2 diabetes mellitus	0.000366	0.00473	CbGeAlD
Regorafenib—RAF1—liver—type 2 diabetes mellitus	0.000364	0.0047	CbGeAlD
Regorafenib—PDGFRA—liver—type 2 diabetes mellitus	0.000343	0.00443	CbGeAlD
Regorafenib—ABL1—adipose tissue—type 2 diabetes mellitus	0.00034	0.0044	CbGeAlD
Regorafenib—UGT1A1—liver—type 2 diabetes mellitus	0.000327	0.00423	CbGeAlD
Regorafenib—KDR—liver—type 2 diabetes mellitus	0.000309	0.004	CbGeAlD
Regorafenib—KIT—liver—type 2 diabetes mellitus	0.000274	0.00354	CbGeAlD
Regorafenib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000271	0.0035	CbGeAlD
Regorafenib—PDGFRB—liver—type 2 diabetes mellitus	0.000268	0.00346	CbGeAlD
Regorafenib—CYP2B6—nephron tubule—type 2 diabetes mellitus	0.00025	0.00323	CbGeAlD
Regorafenib—CYP2C8—kidney—type 2 diabetes mellitus	0.000245	0.00317	CbGeAlD
Regorafenib—ABL1—liver—type 2 diabetes mellitus	0.000239	0.00308	CbGeAlD
Regorafenib—CYP2B6—cardiovascular system—type 2 diabetes mellitus	0.000224	0.0029	CbGeAlD
Regorafenib—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000222	0.00287	CbGeAlD
Regorafenib—CYP2B6—kidney—type 2 diabetes mellitus	0.00022	0.00284	CbGeAlD
Regorafenib—Angiopathy—Valsartan—type 2 diabetes mellitus	0.000219	0.00145	CcSEcCtD
Regorafenib—Hepatobiliary disease—Irbesartan—type 2 diabetes mellitus	0.000218	0.00145	CcSEcCtD
Regorafenib—Decreased appetite—Sitagliptin—type 2 diabetes mellitus	0.000218	0.00145	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Ramipril—type 2 diabetes mellitus	0.000218	0.00145	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000218	0.00144	CcSEcCtD
Regorafenib—Mediastinal disorder—Valsartan—type 2 diabetes mellitus	0.000217	0.00144	CcSEcCtD
Regorafenib—Fatigue—Glimepiride—type 2 diabetes mellitus	0.000217	0.00144	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000217	0.00144	CcSEcCtD
Regorafenib—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.000217	0.00144	CcSEcCtD
Regorafenib—Connective tissue disorder—Metformin—type 2 diabetes mellitus	0.000216	0.00143	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Losartan—type 2 diabetes mellitus	0.000215	0.00143	CcSEcCtD
Regorafenib—Mediastinal disorder—Orlistat—type 2 diabetes mellitus	0.000215	0.00143	CcSEcCtD
Regorafenib—Pain—Sitagliptin—type 2 diabetes mellitus	0.000215	0.00143	CcSEcCtD
Regorafenib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000214	0.00277	CbGeAlD
Regorafenib—Tremor—Gliclazide—type 2 diabetes mellitus	0.000214	0.00142	CcSEcCtD
Regorafenib—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.000213	0.00142	CcSEcCtD
Regorafenib—Alopecia—Valsartan—type 2 diabetes mellitus	0.000213	0.00142	CcSEcCtD
Regorafenib—Anaemia—Gliclazide—type 2 diabetes mellitus	0.000211	0.0014	CcSEcCtD
Regorafenib—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000211	0.0014	CcSEcCtD
Regorafenib—Alopecia—Orlistat—type 2 diabetes mellitus	0.000211	0.0014	CcSEcCtD
Regorafenib—Malnutrition—Valsartan—type 2 diabetes mellitus	0.00021	0.00139	CcSEcCtD
Regorafenib—Malnutrition—Orlistat—type 2 diabetes mellitus	0.000208	0.00138	CcSEcCtD
Regorafenib—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000207	0.00138	CcSEcCtD
Regorafenib—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.000206	0.00137	CcSEcCtD
Regorafenib—Rash—Repaglinide—type 2 diabetes mellitus	0.000206	0.00137	CcSEcCtD
Regorafenib—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000206	0.00136	CcSEcCtD
Regorafenib—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.000205	0.00136	CcSEcCtD
Regorafenib—Urinary tract disorder—Irbesartan—type 2 diabetes mellitus	0.000205	0.00136	CcSEcCtD
Regorafenib—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.000205	0.00136	CcSEcCtD
Regorafenib—Headache—Repaglinide—type 2 diabetes mellitus	0.000204	0.00136	CcSEcCtD
Regorafenib—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.000204	0.00135	CcSEcCtD
Regorafenib—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000204	0.00135	CcSEcCtD
Regorafenib—Connective tissue disorder—Irbesartan—type 2 diabetes mellitus	0.000204	0.00135	CcSEcCtD
Regorafenib—Thrombocytopenia—Glyburide—type 2 diabetes mellitus	0.000203	0.00135	CcSEcCtD
Regorafenib—Urethral disorder—Irbesartan—type 2 diabetes mellitus	0.000203	0.00135	CcSEcCtD
Regorafenib—Angiopathy—Metformin—type 2 diabetes mellitus	0.000199	0.00132	CcSEcCtD
Regorafenib—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000199	0.00132	CcSEcCtD
Regorafenib—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000199	0.00132	CcSEcCtD
Regorafenib—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.000198	0.00131	CcSEcCtD
Regorafenib—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000198	0.00131	CcSEcCtD
Regorafenib—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000197	0.00131	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000196	0.0013	CcSEcCtD
Regorafenib—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000196	0.0013	CcSEcCtD
Regorafenib—Neutropenia—Ramipril—type 2 diabetes mellitus	0.000195	0.0013	CcSEcCtD
Regorafenib—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000194	0.00129	CcSEcCtD
Regorafenib—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000194	0.00129	CcSEcCtD
Regorafenib—Nausea—Repaglinide—type 2 diabetes mellitus	0.000194	0.00129	CcSEcCtD
Regorafenib—Asthenia—Glipizide—type 2 diabetes mellitus	0.000194	0.00129	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000193	0.00128	CcSEcCtD
Regorafenib—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000193	0.00128	CcSEcCtD
Regorafenib—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.000192	0.00128	CcSEcCtD
Regorafenib—Malnutrition—Metformin—type 2 diabetes mellitus	0.000191	0.00127	CcSEcCtD
Regorafenib—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.00019	0.00126	CcSEcCtD
Regorafenib—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000188	0.00125	CcSEcCtD
Regorafenib—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000187	0.00124	CcSEcCtD
Regorafenib—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000186	0.00123	CcSEcCtD
Regorafenib—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000186	0.00123	CcSEcCtD
Regorafenib—Infection—Gliclazide—type 2 diabetes mellitus	0.000185	0.00123	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Ramipril—type 2 diabetes mellitus	0.000185	0.00123	CcSEcCtD
Regorafenib—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000185	0.00123	CcSEcCtD
Regorafenib—Erythema multiforme—Losartan—type 2 diabetes mellitus	0.000184	0.00122	CcSEcCtD
Regorafenib—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	0.000184	0.00122	CcSEcCtD
Regorafenib—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000183	0.00122	CcSEcCtD
Regorafenib—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000183	0.00121	CcSEcCtD
Regorafenib—Myocardial infarction—Ramipril—type 2 diabetes mellitus	0.000183	0.00121	CcSEcCtD
Regorafenib—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	0.000183	0.00121	CcSEcCtD
Regorafenib—Stomatitis—Ramipril—type 2 diabetes mellitus	0.000182	0.00121	CcSEcCtD
Regorafenib—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000181	0.0012	CcSEcCtD
Regorafenib—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000181	0.0012	CcSEcCtD
Regorafenib—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000181	0.0012	CcSEcCtD
Regorafenib—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.00018	0.0012	CcSEcCtD
Regorafenib—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00018	0.0012	CcSEcCtD
Regorafenib—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.00018	0.00119	CcSEcCtD
Regorafenib—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.00018	0.00119	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000179	0.00119	CcSEcCtD
Regorafenib—Tremor—Metformin—type 2 diabetes mellitus	0.000179	0.00119	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000178	0.00118	CcSEcCtD
Regorafenib—CYP2C19—liver—type 2 diabetes mellitus	0.000177	0.00229	CbGeAlD
Regorafenib—Angiopathy—Losartan—type 2 diabetes mellitus	0.000177	0.00118	CcSEcCtD
Regorafenib—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000177	0.00117	CcSEcCtD
Regorafenib—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.000176	0.00117	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000175	0.00116	CcSEcCtD
Regorafenib—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000175	0.00116	CcSEcCtD
Regorafenib—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000173	0.00115	CcSEcCtD
Regorafenib—Alopecia—Losartan—type 2 diabetes mellitus	0.000172	0.00114	CcSEcCtD
Regorafenib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000172	0.00114	CcSEcCtD
Regorafenib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000172	0.00114	CcSEcCtD
Regorafenib—Vomiting—Glipizide—type 2 diabetes mellitus	0.000172	0.00114	CcSEcCtD
Regorafenib—Infection—Valsartan—type 2 diabetes mellitus	0.00017	0.00113	CcSEcCtD
Regorafenib—Rash—Glipizide—type 2 diabetes mellitus	0.00017	0.00113	CcSEcCtD
Regorafenib—Dermatitis—Glipizide—type 2 diabetes mellitus	0.00017	0.00113	CcSEcCtD
Regorafenib—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.00017	0.00113	CcSEcCtD
Regorafenib—Headache—Glipizide—type 2 diabetes mellitus	0.000169	0.00112	CcSEcCtD
Regorafenib—Tremor—Irbesartan—type 2 diabetes mellitus	0.000169	0.00112	CcSEcCtD
Regorafenib—Infection—Orlistat—type 2 diabetes mellitus	0.000168	0.00112	CcSEcCtD
Regorafenib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000168	0.00112	CcSEcCtD
Regorafenib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000168	0.00111	CcSEcCtD
Regorafenib—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000167	0.00111	CcSEcCtD
Regorafenib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000166	0.00111	CcSEcCtD
Regorafenib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000166	0.0011	CcSEcCtD
Regorafenib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000166	0.00214	CbGeAlD
Regorafenib—CYP3A4—kidney—type 2 diabetes mellitus	0.000166	0.00214	CbGeAlD
Regorafenib—Hypertension—Metformin—type 2 diabetes mellitus	0.000165	0.0011	CcSEcCtD
Regorafenib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000165	0.00109	CcSEcCtD
Regorafenib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000164	0.00109	CcSEcCtD
Regorafenib—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000164	0.00109	CcSEcCtD
Regorafenib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000163	0.00108	CcSEcCtD
Regorafenib—Headache—Pioglitazone—type 2 diabetes mellitus	0.000162	0.00108	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000162	0.00107	CcSEcCtD
Regorafenib—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000162	0.00107	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000161	0.00107	CcSEcCtD
Regorafenib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000161	0.00107	CcSEcCtD
Regorafenib—Nausea—Glipizide—type 2 diabetes mellitus	0.00016	0.00106	CcSEcCtD
Regorafenib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00016	0.00106	CcSEcCtD
Regorafenib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00016	0.00106	CcSEcCtD
Regorafenib—Pain—Gliclazide—type 2 diabetes mellitus	0.00016	0.00106	CcSEcCtD
Regorafenib—Tremor—Losartan—type 2 diabetes mellitus	0.000159	0.00106	CcSEcCtD
Regorafenib—Rash—Glimepiride—type 2 diabetes mellitus	0.000159	0.00105	CcSEcCtD
Regorafenib—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000159	0.00105	CcSEcCtD
Regorafenib—Rash—Sitagliptin—type 2 diabetes mellitus	0.000158	0.00105	CcSEcCtD
Regorafenib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000158	0.00105	CcSEcCtD
Regorafenib—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000158	0.00105	CcSEcCtD
Regorafenib—Headache—Glimepiride—type 2 diabetes mellitus	0.000158	0.00105	CcSEcCtD
Regorafenib—Headache—Sitagliptin—type 2 diabetes mellitus	0.000157	0.00104	CcSEcCtD
Regorafenib—Anaemia—Losartan—type 2 diabetes mellitus	0.000157	0.00104	CcSEcCtD
Regorafenib—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000156	0.00103	CcSEcCtD
Regorafenib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000156	0.00103	CcSEcCtD
Regorafenib—Infection—Metformin—type 2 diabetes mellitus	0.000155	0.00103	CcSEcCtD
Regorafenib—CYP2C8—liver—type 2 diabetes mellitus	0.000155	0.002	CbGeAlD
Regorafenib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000153	0.00102	CcSEcCtD
Regorafenib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000153	0.00101	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000153	0.00101	CcSEcCtD
Regorafenib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000153	0.00101	CcSEcCtD
Regorafenib—Leukopenia—Losartan—type 2 diabetes mellitus	0.000152	0.00101	CcSEcCtD
Regorafenib—Skin disorder—Metformin—type 2 diabetes mellitus	0.000152	0.00101	CcSEcCtD
Regorafenib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000151	0.001	CcSEcCtD
Regorafenib—ABCG2—liver—type 2 diabetes mellitus	0.00015	0.00195	CbGeAlD
Regorafenib—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.00015	0.000998	CcSEcCtD
Regorafenib—Nausea—Glimepiride—type 2 diabetes mellitus	0.00015	0.000994	CcSEcCtD
Regorafenib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000149	0.00099	CcSEcCtD
Regorafenib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000149	0.00099	CcSEcCtD
Regorafenib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000149	0.000989	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000148	0.000982	CcSEcCtD
Regorafenib—Alopecia—Ramipril—type 2 diabetes mellitus	0.000148	0.000982	CcSEcCtD
Regorafenib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000148	0.000981	CcSEcCtD
Regorafenib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000147	0.000979	CcSEcCtD
Regorafenib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000147	0.000979	CcSEcCtD
Regorafenib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000147	0.000978	CcSEcCtD
Regorafenib—Infection—Irbesartan—type 2 diabetes mellitus	0.000146	0.000972	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000146	0.000971	CcSEcCtD
Regorafenib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000146	0.000969	CcSEcCtD
Regorafenib—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000146	0.000967	CcSEcCtD
Regorafenib—Pain—Orlistat—type 2 diabetes mellitus	0.000145	0.000962	CcSEcCtD
Regorafenib—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000145	0.000959	CcSEcCtD
Regorafenib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000144	0.000959	CcSEcCtD
Regorafenib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000144	0.000958	CcSEcCtD
Regorafenib—Rash—Bromocriptine—type 2 diabetes mellitus	0.000143	0.000951	CcSEcCtD
Regorafenib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000143	0.000951	CcSEcCtD
Regorafenib—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000143	0.00095	CcSEcCtD
Regorafenib—Headache—Bromocriptine—type 2 diabetes mellitus	0.000142	0.000945	CcSEcCtD
Regorafenib—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000142	0.000944	CcSEcCtD
Regorafenib—ABCB1—retina—type 2 diabetes mellitus	0.000142	0.00183	CbGeAlD
Regorafenib—Dry mouth—Losartan—type 2 diabetes mellitus	0.000141	0.000939	CcSEcCtD
Regorafenib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00014	0.000931	CcSEcCtD
Regorafenib—CYP2B6—liver—type 2 diabetes mellitus	0.000139	0.00179	CbGeAlD
Regorafenib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000139	0.00092	CcSEcCtD
Regorafenib—Infection—Losartan—type 2 diabetes mellitus	0.000138	0.000914	CcSEcCtD
Regorafenib—CYP2C9—liver—type 2 diabetes mellitus	0.000137	0.00178	CbGeAlD
Regorafenib—Tremor—Ramipril—type 2 diabetes mellitus	0.000136	0.000906	CcSEcCtD
Regorafenib—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000136	0.000903	CcSEcCtD
Regorafenib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000136	0.000901	CcSEcCtD
Regorafenib—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000136	0.000901	CcSEcCtD
Regorafenib—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000136	0.0009	CcSEcCtD
Regorafenib—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000135	0.000896	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000135	0.000895	CcSEcCtD
Regorafenib—Fatigue—Metformin—type 2 diabetes mellitus	0.000135	0.000893	CcSEcCtD
Regorafenib—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000134	0.000889	CcSEcCtD
Regorafenib—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000134	0.000889	CcSEcCtD
Regorafenib—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000134	0.000889	CcSEcCtD
Regorafenib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000134	0.00173	CbGeAlD
Regorafenib—Vomiting—Glyburide—type 2 diabetes mellitus	0.000132	0.000877	CcSEcCtD
Regorafenib—Rash—Glyburide—type 2 diabetes mellitus	0.000131	0.00087	CcSEcCtD
Regorafenib—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000131	0.000869	CcSEcCtD
Regorafenib—Leukopenia—Ramipril—type 2 diabetes mellitus	0.00013	0.000866	CcSEcCtD
Regorafenib—Headache—Glyburide—type 2 diabetes mellitus	0.00013	0.000864	CcSEcCtD
Regorafenib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000128	0.00085	CcSEcCtD
Regorafenib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000128	0.000847	CcSEcCtD
Regorafenib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000128	0.000847	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000127	0.000844	CcSEcCtD
Regorafenib—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000127	0.000843	CcSEcCtD
Regorafenib—Pain—Irbesartan—type 2 diabetes mellitus	0.000126	0.000836	CcSEcCtD
Regorafenib—Nausea—Glyburide—type 2 diabetes mellitus	0.000123	0.000819	CcSEcCtD
Regorafenib—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000123	0.000819	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000123	0.000818	CcSEcCtD
Regorafenib—Asthenia—Valsartan—type 2 diabetes mellitus	0.000123	0.000816	CcSEcCtD
Regorafenib—Asthenia—Orlistat—type 2 diabetes mellitus	0.000122	0.000807	CcSEcCtD
Regorafenib—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000121	0.000805	CcSEcCtD
Regorafenib—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000121	0.0008	CcSEcCtD
Regorafenib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00012	0.0008	CcSEcCtD
Regorafenib—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.00012	0.00155	CbGeAlD
Regorafenib—Fatigue—Losartan—type 2 diabetes mellitus	0.00012	0.000794	CcSEcCtD
Regorafenib—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000119	0.000788	CcSEcCtD
Regorafenib—Pain—Losartan—type 2 diabetes mellitus	0.000119	0.000787	CcSEcCtD
Regorafenib—Rash—Gliclazide—type 2 diabetes mellitus	0.000118	0.000781	CcSEcCtD
Regorafenib—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000118	0.00078	CcSEcCtD
Regorafenib—ABCB1—kidney—type 2 diabetes mellitus	0.000117	0.00152	CbGeAlD
Regorafenib—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000117	0.000779	CcSEcCtD
Regorafenib—Headache—Gliclazide—type 2 diabetes mellitus	0.000117	0.000776	CcSEcCtD
Regorafenib—ABCB1—pancreas—type 2 diabetes mellitus	0.000117	0.00151	CbGeAlD
Regorafenib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000117	0.000774	CcSEcCtD
Regorafenib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000116	0.000773	CcSEcCtD
Regorafenib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000116	0.000773	CcSEcCtD
Regorafenib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.000116	0.000773	CcSEcCtD
Regorafenib—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000116	0.000769	CcSEcCtD
Regorafenib—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000115	0.000767	CcSEcCtD
Regorafenib—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000114	0.00148	CbGeAlD
Regorafenib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000113	0.000753	CcSEcCtD
Regorafenib—Asthenia—Metformin—type 2 diabetes mellitus	0.000112	0.000744	CcSEcCtD
Regorafenib—Nausea—Gliclazide—type 2 diabetes mellitus	0.000111	0.000736	CcSEcCtD
Regorafenib—Abdominal pain—Losartan—type 2 diabetes mellitus	0.00011	0.000728	CcSEcCtD
Regorafenib—Body temperature increased—Losartan—type 2 diabetes mellitus	0.00011	0.000728	CcSEcCtD
Regorafenib—Vomiting—Valsartan—type 2 diabetes mellitus	0.000109	0.000724	CcSEcCtD
Regorafenib—Rash—Valsartan—type 2 diabetes mellitus	0.000108	0.000718	CcSEcCtD
Regorafenib—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000108	0.000717	CcSEcCtD
Regorafenib—Vomiting—Orlistat—type 2 diabetes mellitus	0.000108	0.000715	CcSEcCtD
Regorafenib—Headache—Valsartan—type 2 diabetes mellitus	0.000107	0.000713	CcSEcCtD
Regorafenib—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000107	0.000709	CcSEcCtD
Regorafenib—Rash—Orlistat—type 2 diabetes mellitus	0.000107	0.000709	CcSEcCtD
Regorafenib—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000107	0.000708	CcSEcCtD
Regorafenib—Headache—Orlistat—type 2 diabetes mellitus	0.000106	0.000704	CcSEcCtD
Regorafenib—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000106	0.00137	CbGeAlD
Regorafenib—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000106	0.000702	CcSEcCtD
Regorafenib—CYP3A4—liver—type 2 diabetes mellitus	0.000105	0.00136	CbGeAlD
Regorafenib—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000103	0.000686	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000103	0.000681	CcSEcCtD
Regorafenib—Fatigue—Ramipril—type 2 diabetes mellitus	0.000102	0.00068	CcSEcCtD
Regorafenib—Nausea—Valsartan—type 2 diabetes mellitus	0.000102	0.000676	CcSEcCtD
Regorafenib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000101	0.000669	CcSEcCtD
Regorafenib—Nausea—Orlistat—type 2 diabetes mellitus	0.000101	0.000668	CcSEcCtD
Regorafenib—Asthenia—Losartan—type 2 diabetes mellitus	9.95e-05	0.00066	CcSEcCtD
Regorafenib—Vomiting—Metformin—type 2 diabetes mellitus	9.92e-05	0.000659	CcSEcCtD
Regorafenib—Rash—Metformin—type 2 diabetes mellitus	9.84e-05	0.000653	CcSEcCtD
Regorafenib—Dermatitis—Metformin—type 2 diabetes mellitus	9.83e-05	0.000653	CcSEcCtD
Regorafenib—Headache—Metformin—type 2 diabetes mellitus	9.78e-05	0.000649	CcSEcCtD
Regorafenib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	9.72e-05	0.000645	CcSEcCtD
Regorafenib—Diarrhoea—Losartan—type 2 diabetes mellitus	9.49e-05	0.00063	CcSEcCtD
Regorafenib—Abdominal pain—Ramipril—type 2 diabetes mellitus	9.4e-05	0.000624	CcSEcCtD
Regorafenib—Body temperature increased—Ramipril—type 2 diabetes mellitus	9.4e-05	0.000624	CcSEcCtD
Regorafenib—Vomiting—Irbesartan—type 2 diabetes mellitus	9.37e-05	0.000622	CcSEcCtD
Regorafenib—Rash—Irbesartan—type 2 diabetes mellitus	9.29e-05	0.000617	CcSEcCtD
Regorafenib—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.28e-05	0.000616	CcSEcCtD
Regorafenib—Nausea—Metformin—type 2 diabetes mellitus	9.27e-05	0.000616	CcSEcCtD
Regorafenib—Headache—Irbesartan—type 2 diabetes mellitus	9.23e-05	0.000613	CcSEcCtD
Regorafenib—Vomiting—Losartan—type 2 diabetes mellitus	8.81e-05	0.000585	CcSEcCtD
Regorafenib—Nausea—Irbesartan—type 2 diabetes mellitus	8.75e-05	0.000581	CcSEcCtD
Regorafenib—Rash—Losartan—type 2 diabetes mellitus	8.74e-05	0.00058	CcSEcCtD
Regorafenib—Dermatitis—Losartan—type 2 diabetes mellitus	8.73e-05	0.00058	CcSEcCtD
Regorafenib—Headache—Losartan—type 2 diabetes mellitus	8.68e-05	0.000577	CcSEcCtD
Regorafenib—Asthenia—Ramipril—type 2 diabetes mellitus	8.53e-05	0.000566	CcSEcCtD
Regorafenib—Nausea—Losartan—type 2 diabetes mellitus	8.23e-05	0.000547	CcSEcCtD
Regorafenib—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.13e-05	0.00054	CcSEcCtD
Regorafenib—Vomiting—Ramipril—type 2 diabetes mellitus	7.56e-05	0.000502	CcSEcCtD
Regorafenib—Rash—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000498	CcSEcCtD
Regorafenib—Dermatitis—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000497	CcSEcCtD
Regorafenib—Headache—Ramipril—type 2 diabetes mellitus	7.45e-05	0.000494	CcSEcCtD
Regorafenib—ABCB1—liver—type 2 diabetes mellitus	7.42e-05	0.000959	CbGeAlD
Regorafenib—Nausea—Ramipril—type 2 diabetes mellitus	7.06e-05	0.000469	CcSEcCtD
Regorafenib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	1.66e-06	9.85e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AGT—type 2 diabetes mellitus	1.65e-06	9.84e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.65e-06	9.84e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EGFR—type 2 diabetes mellitus	1.65e-06	9.81e-06	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—AKT1—type 2 diabetes mellitus	1.65e-06	9.8e-06	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—type 2 diabetes mellitus	1.64e-06	9.75e-06	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—AKT1—type 2 diabetes mellitus	1.64e-06	9.74e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	1.64e-06	9.74e-06	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—type 2 diabetes mellitus	1.63e-06	9.71e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CALM1—type 2 diabetes mellitus	1.63e-06	9.67e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—type 2 diabetes mellitus	1.62e-06	9.64e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.62e-06	9.61e-06	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—type 2 diabetes mellitus	1.61e-06	9.58e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.61e-06	9.55e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	1.61e-06	9.55e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	1.6e-06	9.53e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOA1—type 2 diabetes mellitus	1.6e-06	9.53e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	1.6e-06	9.5e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	1.6e-06	9.5e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EGFR—type 2 diabetes mellitus	1.59e-06	9.47e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.59e-06	9.46e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.59e-06	9.45e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.59e-06	9.45e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.59e-06	9.44e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	1.58e-06	9.38e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.57e-06	9.36e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.57e-06	9.36e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.57e-06	9.34e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.57e-06	9.32e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.57e-06	9.32e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.56e-06	9.28e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	1.56e-06	9.25e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—SRC—type 2 diabetes mellitus	1.55e-06	9.19e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.54e-06	9.15e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	1.54e-06	9.14e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.53e-06	9.12e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.53e-06	9.11e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	1.53e-06	9.1e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—type 2 diabetes mellitus	1.53e-06	9.09e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—type 2 diabetes mellitus	1.52e-06	9.07e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.52e-06	9.03e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.52e-06	9.01e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—type 2 diabetes mellitus	1.51e-06	9e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.51e-06	9e-06	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—AKT1—type 2 diabetes mellitus	1.51e-06	9e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.51e-06	8.97e-06	CbGpPWpGaD
Regorafenib—BRAF—Disease—AKT1—type 2 diabetes mellitus	1.51e-06	8.96e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.51e-06	8.95e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.5e-06	8.94e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFB1—type 2 diabetes mellitus	1.5e-06	8.92e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.5e-06	8.89e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.49e-06	8.88e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	1.49e-06	8.85e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.49e-06	8.85e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—type 2 diabetes mellitus	1.49e-06	8.84e-06	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—type 2 diabetes mellitus	1.49e-06	8.84e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.48e-06	8.79e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.48e-06	8.79e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	1.47e-06	8.77e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—type 2 diabetes mellitus	1.47e-06	8.75e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.47e-06	8.72e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	1.46e-06	8.7e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.46e-06	8.7e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SRC—type 2 diabetes mellitus	1.46e-06	8.7e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	1.46e-06	8.69e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	1.46e-06	8.66e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.45e-06	8.64e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.45e-06	8.62e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	1.45e-06	8.6e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.44e-06	8.56e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.44e-06	8.56e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.44e-06	8.56e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	1.44e-06	8.55e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.43e-06	8.51e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	1.43e-06	8.51e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.43e-06	8.5e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.43e-06	8.5e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.43e-06	8.48e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	1.43e-06	8.48e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.43e-06	8.47e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.42e-06	8.45e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.41e-06	8.41e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PPARG—type 2 diabetes mellitus	1.41e-06	8.4e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—type 2 diabetes mellitus	1.41e-06	8.39e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—type 2 diabetes mellitus	1.41e-06	8.39e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—type 2 diabetes mellitus	1.41e-06	8.37e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.41e-06	8.37e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—type 2 diabetes mellitus	1.41e-06	8.36e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.41e-06	8.36e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	1.4e-06	8.33e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—type 2 diabetes mellitus	1.4e-06	8.31e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.4e-06	8.3e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	1.4e-06	8.3e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.39e-06	8.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.39e-06	8.26e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	1.39e-06	8.26e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—INS—type 2 diabetes mellitus	1.39e-06	8.24e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.38e-06	8.22e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.38e-06	8.2e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	1.38e-06	8.19e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	1.37e-06	8.17e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	1.37e-06	8.16e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—type 2 diabetes mellitus	1.37e-06	8.16e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	1.37e-06	8.15e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	1.36e-06	8.07e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	1.36e-06	8.07e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.36e-06	8.06e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.36e-06	8.06e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.35e-06	8.02e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—type 2 diabetes mellitus	1.34e-06	7.99e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.34e-06	7.97e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.34e-06	7.96e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—type 2 diabetes mellitus	1.34e-06	7.96e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	1.33e-06	7.92e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	1.32e-06	7.84e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	1.32e-06	7.83e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.31e-06	7.8e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.31e-06	7.8e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.31e-06	7.78e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	1.3e-06	7.76e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—type 2 diabetes mellitus	1.3e-06	7.74e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	1.3e-06	7.73e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—type 2 diabetes mellitus	1.3e-06	7.72e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.29e-06	7.68e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.29e-06	7.68e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.29e-06	7.68e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	1.29e-06	7.68e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.29e-06	7.65e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.28e-06	7.64e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.28e-06	7.63e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.28e-06	7.63e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.27e-06	7.58e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—type 2 diabetes mellitus	1.27e-06	7.55e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	1.27e-06	7.54e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.27e-06	7.54e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	1.27e-06	7.53e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	1.27e-06	7.53e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.26e-06	7.5e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.26e-06	7.49e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.26e-06	7.47e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	1.25e-06	7.44e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	1.25e-06	7.44e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.24e-06	7.37e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.24e-06	7.35e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	1.23e-06	7.34e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.23e-06	7.31e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	1.23e-06	7.31e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	1.23e-06	7.29e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—type 2 diabetes mellitus	1.22e-06	7.28e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.22e-06	7.26e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—type 2 diabetes mellitus	1.21e-06	7.22e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.21e-06	7.22e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	1.21e-06	7.2e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.2e-06	7.14e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	1.2e-06	7.14e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.2e-06	7.11e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	1.2e-06	7.11e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.18e-06	7.03e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.18e-06	7.03e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.18e-06	7.01e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	1.18e-06	7e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.18e-06	6.99e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	1.17e-06	6.97e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	1.17e-06	6.96e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.17e-06	6.95e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.17e-06	6.95e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.16e-06	6.87e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—type 2 diabetes mellitus	1.15e-06	6.87e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.14e-06	6.81e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—type 2 diabetes mellitus	1.14e-06	6.8e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	1.14e-06	6.78e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—type 2 diabetes mellitus	1.13e-06	6.72e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—type 2 diabetes mellitus	1.13e-06	6.72e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	1.12e-06	6.67e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.12e-06	6.66e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.12e-06	6.66e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	1.12e-06	6.64e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—type 2 diabetes mellitus	1.11e-06	6.61e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	1.1e-06	6.57e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	1.08e-06	6.39e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	1.07e-06	6.35e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.07e-06	6.34e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.06e-06	6.3e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.06e-06	6.28e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.05e-06	6.25e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	1.05e-06	6.22e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—type 2 diabetes mellitus	1.04e-06	6.2e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.04e-06	6.19e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—type 2 diabetes mellitus	1.04e-06	6.19e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.03e-06	6.12e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	1.03e-06	6.11e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	1.03e-06	6.11e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.02e-06	6.07e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—type 2 diabetes mellitus	9.88e-07	5.88e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—type 2 diabetes mellitus	9.86e-07	5.86e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.78e-07	5.82e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	9.73e-07	5.79e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	9.65e-07	5.74e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	9.65e-07	5.74e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	9.61e-07	5.71e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.61e-07	5.71e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	9.6e-07	5.71e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	9.54e-07	5.67e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	9.48e-07	5.64e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	9.41e-07	5.59e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	9.37e-07	5.57e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	9.21e-07	5.47e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	9.18e-07	5.46e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	9.18e-07	5.46e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.12e-07	5.42e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.09e-07	5.41e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—type 2 diabetes mellitus	8.98e-07	5.34e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—type 2 diabetes mellitus	8.98e-07	5.34e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	8.96e-07	5.33e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	8.96e-07	5.33e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	8.96e-07	5.32e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	8.88e-07	5.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	8.79e-07	5.23e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	8.75e-07	5.2e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	8.61e-07	5.12e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	8.58e-07	5.1e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	8.4e-07	4.99e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	8.37e-07	4.98e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	8.37e-07	4.98e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	8.35e-07	4.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	8.25e-07	4.9e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	8.19e-07	4.87e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.19e-07	4.87e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—type 2 diabetes mellitus	7.92e-07	4.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	7.91e-07	4.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	7.76e-07	4.62e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	7.66e-07	4.55e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	7.62e-07	4.53e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	7.52e-07	4.47e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	7.39e-07	4.4e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	7.37e-07	4.38e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.3e-07	4.34e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	7.28e-07	4.33e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	6.42e-07	3.82e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	6.29e-07	3.74e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	5.77e-07	3.43e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—type 2 diabetes mellitus	5.58e-07	3.32e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	5.52e-07	3.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	5.52e-07	3.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	5.05e-07	3e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	4.73e-07	2.81e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	4.22e-07	2.51e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	4.12e-07	2.45e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	3.85e-07	2.29e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.54e-07	1.51e-06	CbGpPWpGaD
